Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhibitors, ...
Mass Spec Alternative Detects Biomarker Signatures in Tissues, Blood, and Cell Culture The current generation of antibody microarray technologies is providing highly sensitive new tools for screening ...
A prospective pharmacogenetic study of thymidylate synthase (TS) polymorphisms in high risk stage II or stage III colon cancer patients treated with 5-fluorouracil (5-FU) and leucovorin (LV) ...
BERKELEY, CA — The dream of personalized medicine — in which diagnostics, risk predictions and treatment decisions are based on a patient's genetic profile — may be on the verge of being expanded ...
In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.
The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...
Development of an immunoglobin variable region specific DNA microarray: Analysis of B-Cell clonality
The prophylactic use of lamivudine can maintain dose-intensity of doxorubicin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who received cytotoxic chemotherapy ...
During the continued progression of the coronavirus pandemic, rapid, inexpensive, and reliable tests will become increasingly important to determine whether people have the associated antibodies -- ...
EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac Disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback